Brief: Expres2ion Biotech Says DSMB Recommends Expanding 450 Μg Cohort
12/08/2026 12:46
BRIEF-Expres2ion Biotech Says DSMB Recommends Expanding 450 Μg Cohort Aug 12 (Reuters) - ExpreS2ion Biotech Holding AB EXPRS2.ST:
DSMB FINDS NO DOSE-LIMITING TOXICITIES AND RECOMMENDS EXPANDING 450 ΜG COHORT
PRELIMINARY DATA SHOW ANTI-HER2 ANTIBODY RESPONSES IN 12 OF 13 PATIENTS WITH 16-FOLD PEAK INCREASE
PHASE I PRIMARY READOUT TARGET OF END-2026 IS UNCHANGED.
PHASE II INITIATION IS NOW TARGETED FOR SECOND HALF OF 2027
Source text: ID:nMFN8KSKlb
Further company coverage: EXPRS2.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on ExpreS2ion Biotech Holding AB
See all newsBrief: Expres2ion Biotech To Raise SEK 19.3 Million From Warrants And Share Issue
Brief: ExpreS2ion Reports Q2 Loss Of SEK 9.7 Million
Brief: Expres2ion Biotech Says DSMB Recommends Expanding 450 Μg Cohort
Brief: Expres2ion Biotech Holding Q1 2026 Operating Income SEK 6.87 Mln
Brief: Expres2ion Updates ES2B-C001 Phase I Programme and Reports Additional Preliminary Immunogenicity and Safety Observations